Higher Medicine
Higher Medicine is a Baltimore-based biotechnology company developing small-molecule therapies that target epigenetic dysregulation and mitochondrial dysfunction for rare neurodevelopmental and neurodegenerative disorders. Programs described include an LSD1 inhibitor program targeting Kabuki Syndrome and a p38 MAP kinase inhibitor program for Friedreich’s ataxia. The company develops epigenetic reporter assays and phenotypic screening tools, pursues IND-enabling preclinical studies, and engages in strategic partnerships, licensing, accelerator participation, and early‑phase clinical planning.
Industries
Nr. of Employees
small (1-50)
Products
Epigenetic reporter allele screening platform
A DNA construct–based reporter system that provides a real-time phenotypic readout of gene-specific methylation states to identify chromatin-modifying small molecules in vitro and in vivo.
LSD1 inhibitor program (Kabuki Syndrome)
Small-molecule program targeting LSD1 to modulate chromatin remodeling and address transcriptional dysregulation associated with Kabuki Syndrome; advanced toward preclinical validation and clinical planning.
p38 MAP kinase inhibitor program (Friedreich’s ataxia)
Small-molecule p38 MAP kinase inhibitor program intended to modulate cellular stress responses and improve mitochondrial health in Friedreich’s ataxia.
Epigenetic reporter allele screening platform
A DNA construct–based reporter system that provides a real-time phenotypic readout of gene-specific methylation states to identify chromatin-modifying small molecules in vitro and in vivo.
LSD1 inhibitor program (Kabuki Syndrome)
Small-molecule program targeting LSD1 to modulate chromatin remodeling and address transcriptional dysregulation associated with Kabuki Syndrome; advanced toward preclinical validation and clinical planning.
p38 MAP kinase inhibitor program (Friedreich’s ataxia)
Small-molecule p38 MAP kinase inhibitor program intended to modulate cellular stress responses and improve mitochondrial health in Friedreich’s ataxia.
Services
Operational delivery and support for early-phase clinical studies through strategic CRO partnerships (feasibility, regulatory submissions, data management, safety monitoring).
Operational delivery and support for early-phase clinical studies through strategic CRO partnerships (feasibility, regulatory submissions, data management, safety monitoring).
Expertise Areas
- Epigenetic drug discovery
- Small-molecule therapeutic development
- Rare disease therapeutics (Kabuki Syndrome, Friedreich’s ataxia)
- Phenotypic screening and reporter assay development
Key Technologies
- Epigenetic reporter assays (histone reporter allele constructs)
- Phenotypic high-resolution screening (in vitro and in vivo)
- Small-molecule medicinal chemistry
- LSD1-targeted inhibitor development
News & Updates
Received a $100,000 Pre-Seed Builder Fund investment from TEDCO to support development activities.
Entered into an exclusive option agreement with a university tech‑transfer office to advance a histone reporter allele platform for epigenetic drug discovery.
Announced a strategic investment and clinical development agreement with an investor group; clinical execution planned with a CRO to support an upcoming Phase 1b/2a study.
Awarded a competitive EDGE grant to support IND‑enabling regulatory research, lead compound validation, and team building.
Formed a Delaware-based subsidiary dedicated to developing a p38 MAP kinase inhibitor program for Friedreich’s ataxia.
Selected for an accelerator program providing mentorship, training, and support to scale the company and secure follow-on funding.
Received a $100,000 Pre-Seed Builder Fund investment from TEDCO to support development activities.
Entered into an exclusive option agreement with a university tech‑transfer office to advance a histone reporter allele platform for epigenetic drug discovery.
Announced a strategic investment and clinical development agreement with an investor group; clinical execution planned with a CRO to support an upcoming Phase 1b/2a study.
Awarded a competitive EDGE grant to support IND‑enabling regulatory research, lead compound validation, and team building.
Formed a Delaware-based subsidiary dedicated to developing a p38 MAP kinase inhibitor program for Friedreich’s ataxia.
Selected for an accelerator program providing mentorship, training, and support to scale the company and secure follow-on funding.